Benign Prostatic Hyperplasia Market Size Analysis, Growth Opportunities, Pipeline Development Activities, Emerging Therapies, and Epidemiology Forecast by DelveInsight

DelveInsight's Benign Prostatic Hyperplasia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Benign Prostatic Hyperplasia (BPH), historical and forecasted epidemiology as well as the Benign Prostatic Hyperplasia (BPH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Benign Prostatic Hyperplasia Overview
Benign prostatic hyperplasia-also called BPH-is a condition in men in which the prostate gland is enlarged and not cancerous. Benign prostatic hyperplasia is also called benign prostatic hypertrophy or benign prostatic obstruction. As the prostate enlarges, the gland presses against and pinches the urethra. The bladder wall becomes thicker. Eventually, the bladder may weaken and lose the ability to empty completely, leaving some urine in the bladder. The narrowing of the urethra and urinary retention-the inability to empty the bladder completely-cause many of the problems associated with benign prostatic hyperplasia.

Download Sample Report- https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Regions covered in the report
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Key highlights of the Benign Prostatic Hyperplasia Market
• As per a study conducted by Lim et al. (2017), the histological prevalence of BPH was observed as 8%, 50%, and 80% in the 4th, 6th, and 9th decades of life, respectively
• BPH is the most common prostate problem for men older than age 50
• BPH is more common in older males as compared to those below 40 years
• A study conducted by Lee et al. (2017), showed that the median point prevalence of BPH was 25.2%. The study also showed that there was an increasing prevalence of lower urinary tract symptoms (LUTS)/BPH with age

Benign Prostatic Hyperplasia Cause
The cause of benign prostatic hyperplasia is not well understood; however, it occurs mainly in older men. Benign prostatic hyperplasia does not develop in men whose testicles were removed before puberty. For this reason, some researchers believe factors related to the testicles may cause benign prostatic hyperplasia. Scientific studies have suggested that benign prostatic hyperplasia may occur because the higher proportion of estrogen within the prostate increases the activity of substances that promote prostate cell growth.

Benign Prostatic Hyperplasia Symptoms:
The symptoms of Benign Prostatic Hyperplasia include -
• Frequent need to urinate
• Difficulty in urinating
• Weak urine stream
• Inability to empty the bladder
• Dibbling at the end of urination

Benign Prostatic Hyperplasia Market
The dynamics of the Benign Prostatic Hyperplasia (BPH) market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as QLT0074, PRX302, and others during the forecasted period 2019-2032.

Benign Prostatic Hyperplasia Pipeline Therapies:
• Tadalafil
• PRX302
• Tamsulosin OCAS
• QLT0074
• Silodosin, and several others

Benign Prostatic Hyperplasia Pipeline Companies:
• Dongkook Pharmaceutical
• ICOS Corporation
• Mundipharma Research
• Astellas Pharma, and several others

Request Sample Report- https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Benign prostatic hyperplasia Executive Summary
3. Benign prostatic hyperplasia Competitive Intelligence Analysis
4. Benign prostatic hyperplasia Market Overview at a Glance
5. Benign prostatic hyperplasia Disease Background and Overview
6. Patient Journey
7. Benign prostatic hyperplasia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Benign prostatic hyperplasia Unmet Needs
10. Key Endpoints of Benign prostatic hyperplasia Treatment
11. Benign prostatic hyperplasia Marketed Products
12. Benign prostatic hyperplasia Emerging Therapies
13. Benign prostatic hyperplasia Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Benign prostatic hyperplasia Market Outlook
16. Access and Reimbursement Overview
17. KOL Views
18. Benign prostatic hyperplasia Market Drivers
19. Benign prostatic hyperplasia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Do you have any query or doubt related to the report? If yes, visit here- https://www.delveinsight.com/report-store/benign-prostatic-hyperplasia-bph-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Yash
info@delveinsight.com

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.